Quanterix has introduced the new biomarker blood test, LucentAD, to facilitate the diagnosis of Alzheimer’s disease (AD) in patients.
The test has been designed to help assess patients experiencing cognitive symptoms consistent with the early signs of AD.
Healthcare providers can use this test along with other diagnostic tools to rapidly evaluate the likelihood of a patient having amyloid pathology consistent with the disease.
Designed to be run by the company’s clinical laboratory improvement amendments (CLIA), the test measures phosphorylated tau protein isoform in plasma.
